DKC1 is a direct and conserved transcriptional target of c-MYC

Biochemical and Biophysical Research Communications

Volumn 362, Issue 4, 2007, Pages 893-898

  Alawi, Faizan ^a   Lee, Megan N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

c MYC estrogen receptor; Dyskerin; E box; Gene regulation; Ribosome biogenesis; Telomerase

Indexed keywords

DYSKERIN; MYC PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DKC1 GENE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC CONSERVATION; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; INTRON; NONHUMAN; ONCOGENE C MYC; PHYLOGENY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RODENT; TRANSGENE; UPREGULATION;

CELL CYCLE PROTEINS; CELL LINE; CONSERVED SEQUENCE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENE TARGETING; GENES, MYC; HUMANS; NUCLEAR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

RODENTIA;

EID: 34548562074     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.08.071     Document Type: Article

References (25)

1. Heiss N.S., Knight S.W., Vulliamy T.J., Klauck S.M., Wiemann S., Mason P.J., Poustka A., and Dokal I. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19 (1998) 32-38
2. Mitchell J.R., Wood E., and Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402 (1999) 551-555
3. Ruggero D., Grisendi S., Piazza F., Rego E E., Mari F., Rao P.H., Cordon-Cardo C., and Pandolfi P.P. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 299 (2003) 259-262
4. Yoon A., Peng G., Brandenburger Y., Zollo O., Xu W., Rego E., and Ruggero D. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 312 (2006) 902-906
5. Soung Y.H., Lee J.W., Kim S.Y., Nam S.W., Park W.S., Lee J.Y., Yoo N.J., and Lee S.H. Absence of DKC1 exon 3 mutation in common human cancers. Acta Oncol. 45 (2006) 342-343
6. Montanaro L., Brigotti M., Clohessy J., Barbieri S., Ceccarelli C., Santini D., Taffurelli M., Calienni M., Teruya-Feldstein J., Trere D., Pandolfi P.P., and Derenzini M. Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J. Pathol. 210 (2006) 10-18
7. McDonald S.L., Edington H.D., Kirkwood J.M., and Becker D. Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes. Cancer Biol. Ther. 3 (2004) 110-120
8. Killian A., Sarafan-Vasseur N., Sesboue R., Le Pessot F., Blanchard F., Lamy A., Laurent M., Flaman J.M., and Frebourg T. Contribution of the BOP1 gene, located on 8q24, to colorectal tumorigenesis. Genes Chromosomes Cancer 45 (2006) 874-881
9. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6 (2005) 635-645
10. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., and Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 21 (1999) 220-224
11. Schlosser I., Holzel M., Murnseer M., Burtscher H., Weidle U.H., and Eick D. A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res. 31 (2003) 6148-6156
12. Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., Cocito A., and Amati B. Genomic targets of the human c-Myc protein. Genes Dev. 17 (2003) 1115-1129
13. O'Connell B.C., Cheung A.F., Simkevich C.P., Tam W., Ren X., Mateyak M.K., and Sedivy J.M. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J. Biol. Chem. 278 (2003) 12563-12573
14. Zeller K.I., Zhao X., Lee C.W., Chiu K.P., Yao F., Yustein J.T., Ooi H.S., Orlov Y.L., Shahab A., Yong H.C., Fu Y., Weng Z., Kuznetsov V.A., Sung W.K., Ruan Y., Dang C.V., and Wei C.L. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc. Natl. Acad. Sci. USA 103 (2006) 17834-17839
15. Pajic A., Spitkovsky D., Christoph B., Kempkes B., Schuhmacher M., Staege M.S., Brielmeier M., Ellwart J., Kohlhuber F., Bornkamm G.W., Polack A., and Eick D. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int. J. Cancer 87 (2000) 787-793
16. Dews M., Homayouni A., Yu D., Murphy D., Sevignani C., Wentzel E., Furth E.E., Lee W.M., Enders G.H., Mendell J.T., and Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 38 (2006) 1060-1065
17. Su A.I., Cooke M.P., Ching K.A., Hakak Y., Walker J.R., Wiltshire T., Orth A.P., Vega R.G., Sapinoso L.M., Moqrich A., Patapoutian A., Hampton G.M., Schultz P.G., and Hogenesch J.B. Large-scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. USA 99 (2002) 4465-4470
18. O'Donnell K.A., Yu D., Zeller K.I., Kim J.W., Racke F., Thomas-Tikhonenko A., and Dang C.V. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol. Cell Biol. 26 (2006) 2373-2386
19. Blackwell T.K., Huang J., Ma A., Kretzner L., Alt F.W., Eisenman R.N., and Weintraub H. Binding of myc proteins to canonical and noncanonical DNA sequences. Mol. Cell Biol. 13 (1993) 5216-5224
20. Haggerty T.J., Zeller K.I., Osthus R.C., Wonsey D.R., and Dang C.V. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc. Natl. Acad. Sci. USA 100 (2003) 5313-5318
21. Zhang X.Y., DeSalle L.M., Patel J.H., Capobianco A.J., Yu D., Thomas-Tikhonenko A., and McMahon S.B. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc. Natl. Acad. Sci. USA 102 (2005) 13968-13973
22. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., and Li F. The c-Myc target gene network. Semin. Cancer Biol. 16 (2006) 253-264
23. Barrett J.F., Lee L.A., and Dang C.V. Stimulation of Myc transactivation by the TATA binding protein in promoter-reporter assays. BMC Biochem. 6 (2005) 7-22
24. Salowsky R., Heiss N.S., Benner A., Wittig R., and Poustka A. Basal transcription activity of the dyskeratosis congenita gene is mediated by Sp1 and Sp3 and a patient mutation in a Sp1 binding site is associated with decreased promoter activity. Gene 293 (2002) 9-19
25. Kim J.W., Zeller K.I., Wang Y., Jegga A.G., Aronow B.J., O'Donnell K.A., and Dang C.V. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol. Cell Biol. 24 (2004) 5923-5936